2. Papaharitou S., Athanasiadis L., Nakopoulou E., Kirana P., Portseli A., Iraklidou M., Hatzimouratidis K., Hatzichristou D. Erectile dysfunction and premature ejaculation are the most frequently self-reported sexual concerns: profiles of 9,536 men calling a helpline. Eur Urol. 2006;49:557–563. Doi: 10.1016/j.eururo.2005.09.023.

3. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.

4. Aytac I.A., McKinlay J.B., Krane R.J. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50–56.

5. Kostis J.B., Jackson G., Rosen R., Barrett-Connor E., Billups K., Burnett A.L., Carson C. 3rd, Cheitlin M., Debusk R., Fonseca V., Ganz P., Goldstein I., Guay A., Hatzichristou D., Hollander J.E., Hutter A., Katz S., Kloner R.A., Mittleman M., Montorsi F., Montorsi P., Nehra A., Sadovsky R., Shabsigh R. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005 Jul 15;96(2):313–321. Doi: 10.1016/j.amjcard.2005.03.065.

6. Pushkar DIu, Kamalov A.A., Al’-Shukri SKh, Erkovich A.A., Kogan M.I., Pavlov V.N., Zhuravlev V.N., Bernikov A.N. Analysis of the results of epidemiological study on prevalence of erectile dysfunction in the Russian Federation]. Urologiia. 2012;(6):5–9 (Пушкарь Д.Ю., Камалов А.А., Аль-Шукри С.Х., Еркович А.А., Коган М.И., Павлов В.Н., Журавлев В.Н., Берников А.Н. Анализ результатов эпидемиологического исследования распространенности эректильной дисфункции в Российской Федерации. Урология. 2012;6:5–9).

7. Hatzichristou D.G., Pescatori E.S. Current treatments and emerging therapeutic approaches in male erectile dysfunction. BJU Int. 2001;88(Suppl. 3):11–17.

8. Lewis R., Bennett C.J., Borkon W.D., Boykin W.H., Althof S.E., Stecher V.J., Siegel R.L. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology. 2001;57:960–965.

9. Steers W., Guay A.T., Leriche A., Gingell C., Hargreave T.B., Wright P.J., Price D.E., Feldman R.A. Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment. Int J Impot Res. 2001;13:261–267.

10. McVary K.T. Erectile dysfunction. New Engl. J. Med. 2007; 357: 2472–2481. Doi: 10.1056/NEJMcp067261.

11. Vardi Y., Bulus M., Reisner S., Nassar S., Aboud .L, Sprecher E., Gruenwald I. Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. Eur Urol. 2003;43(5):544–551.

12. Lokshin K.L. Comparative characteristics of sildenafil and other inhibitors of phosphodiesterase type 5 in the treatment of patients with erectile dysfunction (review of the literature). Russian Medical Journal. 2013;18:936–939 (Локшин К.Л. Сравнительная характеристика силденафила и других ингибиторов фосфодиэстеразы 5-го типа в лечении больных эректильной дисфункцией (обзор литературы). Русский медицинский журнал. 2013;18:936–939).

13. Carson CC III. Sildenafil: A 4-Year Update in the Treatment of 20 Million Erectile Dysfunction Patients. Current Urology Reports 2003, 4:488–496.

14. Kloner R.A., Brown M., Prisant L.M. Collins M. Effect of sildenafil in patients with erectile dysfunction takin antihypertensive therapy. AJH 2001;14:70–73.

15. Carson C.C., Burnett A.L., Levine L.A., Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology. 2002 Sep;60 (2 Suppl 2):12–27.

16. Padma-Nathan H., Stecher V., Sweeney M., Orazem J. Tseng L.-J., Deriesthal H. Minimal time to successful intercourse after sildenafil citrate: results of randomized, double-blind, placebo-controlled trial. Urology. 2003;62:400–403.

17. John P.M., Hassan T.A., Rienow J.347 Understanding the Sexual Habits of Men Taking Medication for Erectile Dysfunction (ED): Survey Results From 7 Countries. J Sex Med 2017:14:1:S102. Doi: https://doi.org/10.1016/j.jsxm.2016.11.235.

18. Claes H., Opsomer R.J., Andrianne R., Vanbelle S., Albert A., Vanderdonck F. Characteristics and expectations of patients with erectile dysfunction: results of the SCORED study. Int J Impot Res. 2008;20(4):418–424. Doi: 10.1038/ijir.2008.7.

19. Tarasov N.I., Bavilsky V.F., Matygin A.S. Long-term monotherapy of sildenafil citrate with various forms of erectile dysfunction. Clinical Pharmacology and Therapy. 2009;18(2):34–37 (Тарасов Н.И., Бавильский В.Ф., Матыгин А.С. Длительная монотерапия силденафила цитратом при различных формах эректильной дисфункции. Клиническая фармакология и терапия. 2009;18(2):34–37).

20. Fusco F., Razzoli E., Imbimbo C., Rossi A., Verze P., Mirone V. A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. BJU Int. 2010 Jun;105(12):1634–1639. Doi: 10.1111/j.1464-410X.2010.09244.x.

21. Cappelleri J.C., Althof S.E., Siegel R.L., Shpilsky A., Bell S.S., Duttagupta S. Development and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction. Int J Impot Res. 2004 Feb;16(1):30–38. Doi: 10.1038/sj.ijir.3901095.

22. Raina R., Lakin M.M., Agarwal A., Sharma R., Goyal K.K., Montague D.K., Klein E., Zippe C.D. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology. 2003;62(1):110–115.

23. Hong E.K., Lepor H., McCullough A.R. Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). Int J Impot Res. 1999 Sep;11(Suppl 1):S15–22.

24. Padma-Nathan H., McCullough A., Forest C. Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Curr Urol Rep. 2004;5(6):467–471.

25. Jannini E.A., Isidori A.M., Gravina G.L., Aversa A., Balercia G., Bocchio M., Boscaro M., Carani C., Corona G., Fabbri A., Foresta C., Forti G., Francavilla S., Granata A.R., Maggi M., Mansani R., Palego P., Spera G., Vetri M., Lenzi A. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil and vardenafil in the treatment of erectile dysfunction. J Sex Med 2009;6:2547–2560. Doi: 10.1111/j.1743-6109.2009.01375.x.

26. Hatzimouratidis K., Giuliano F., Moncada I., Muneer A., Salonia A., Verze P., Parnham A., Serefoglu E.C. EAU Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism, 2017.

27. McMurray J.G., Feldman R.A., Auerbach S.M., Deriesthal H., Wilson N. Multicenter Study Group. Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag. 2007;3(6):975–981.

28. Montorsi F., Briganti A., Salonia A., et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol. 2003;44:360–364.

29. Jackson G., Boon N., Eardley I., Kirby M., Dean J., Hackett G., Montorsi P., Montorsi F., Vlachopoulos C., Kloner R., Sharlip I., Miner M. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int. J. Clin. Pract. 2010;64(7):848‒857. Doi: 10.1111/j.1742-1241.2010.02410.x.

30. Boshier A., Wilton L.V., Shakir S.A. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU Int. 2004;93:796–801. Doi: 10.1111/j.1464-410X.2003.04744.x.

31. Katz S.D., Balidemaj K., Homma S., Wu H., Wang J., Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:845–851.

32. Desouza C., Parulkar A., Lumpkin D., Akers D., Fonseca V.A. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care. 2002;25:1336–1339.

33. Gori T., Sicuro S., Dragoni S., Donati G., Forconi S., Parker J.D. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation. 2005;111:742–746. Doi: 10.1161/01.CIR.0000155252.23933.2D.

34. Hirata K., Adji A., Vlachopoulos C., O’Rourke M.F. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol. 2005;96:1436–1440. Doi: 10.1016/j.amjcard.2005.06.091.

35. Gillies H.C., Roblin D., Jackson G. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol. 2002;86:131–141.

36. Vlachopoulos C., Hirata K., O’Rourke M.F. Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med. 2003;8:243–248. Doi: 10.1191/1358863x03vm509ra.

37. Kukreja R.C., Ockaili R., Salloum F., Yin C., Hawkins J., Das A., Xi L. Cardioprotection with phosphodiesterase-5 inhibition-a novel preconditioning strategy. J Mol Cell Cardiol. 2004;36:165–173. Doi: 10.1016/j.yjmcc.2003.11.001.

38. Webster L.J., Michelakis E.D., Davis T., et al. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med. 2004;164:514–520. Doi: 10.1001/archinte.164.5.514.

39. Borlaug B.A., Melenovsky V., Marhin T., Fitzgerald P., Kass D.A. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation. 2005;112:2642–2649. Doi: 10.1161/CIRCULATIONAHA. 105.540500.

40. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., Bedja D., Gabrielson K.L., Wang Y., Kass D.A. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214–222. Doi: 10.1038/nm1175.

41. Ghofrani H.A., Voswinckel R., Reichenberger F., Olschewski H., Haredza P., Karadaş B., Schermuly R.T., Weissmann N., Seeger W., Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004;44(7):1488–1496. Doi: 10.1016/j.jacc.2004.06.060.

42. Lee A.J., Chiao T.B., Tsang M.P. Sildenafil for Pulmonary Hypertension. Ann Pharmacother 2005;39(5):869–884. Doi: 10.1345/aph.1E426.

43. Rosengarten B., Schermuly R.T., Voswinckel R., Kohstall M.G., Olschewski H., Weissmann N., Seeger W., Kaps M., Grimminger F., Ghofrani H.A. Sildenafil improves dynamic vascu-lar function in the brain: studies in patients with pulmonary hypertension. Cerebrovasc, Dis 2006;21(3):194–200. Doi: 10.1159/000090555.

44. Chua R., Keogh A., Miyashita M. Novel use of sildenafil in the treatment of portopulmon-ary hypertension. J Heart Lung Transplant. 2005;24(4):498–500. Doi: 10.1016/j.healun.2004.01.017.

45. Galiè N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17;353(20):2148–2157. Erratum in: N Engl J Med. 2006;354(22):2400–2401. Doi: 10.1056/NEJMoa050010.

46. Tarlovskaya E.I. Generics in real clinical practice. Arterialnaya Hypertensia, 2009;5(4):512–515. Russian (Тарловская Е.И. Генерики в реальной клинической практике. Артериальная гипертензия. 2009;5(4):512–515).

47. Khubieva M.J. Problems of quality and therapeutic equivalence of generics, Zdravookhranenie. 2010;11:5–27. Russian (Хубиева М.Ю. Проблемы качества и терапевтической эквивалентности дженериков. Здравоохранение. 2010;11:5–27).

48. Vertkin A.L., Talibov O.B. Generics and equivalence – that stands for the terms. Neotlozhnaya terapia. 2004;1–2:16–17. Russian (Верткин А.Л., Талибов О.Б. Генерики и эквивалентность – что стоит за терминами. Неотложная терапия. 2004;1–2:16–17).